1. Generics Bulletin
  2. >>Archive

CPTPP deal drops IP increases

Several provisions that would have increased protection for intellectual property (IP) on pharmaceuticals have been omitted from a Comprehensive and Progressive Agreement for a Trans-Pacific Partnership (CPTPP) trade deal agreed by 11 countries on 23 January, and set to be signed on 8 March in Chile. The agreement struck in Tokyo, Japan, between ministers from Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam includes an annex of suspended provisions – several of which cover IP rights for pharmaceuticals – that were included in the draft Trans-Pacific Partnership (TPP) text before the US pulled out of the trade deal last year. These include requirements for data exclusivity of “at least five years” for small molecules and “at least eight years” for biological drugs, as well as patent-term extensions (Generics bulletin, 24 November 2017, page 1). All CPTPP members would have to agree to reinstate such measures for them to apply in future.

Several provisions that would have increased protection for intellectual property (IP) on pharmaceuticals have been omitted from a Comprehensive and Progressive Agreement for a Trans-Pacific Partnership (CPTPP) trade deal agreed by 11 countries on 23 January, and set to be signed on 8 March in Chile. The agreement struck in Tokyo, Japan, between ministers from Australia, Brunei, Canada, Chile, Japan, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam includes an annex of suspended provisions – several of which cover IP rights for pharmaceuticals – that were included in the draft Trans-Pacific Partnership (TPP) text before the US pulled out of the trade deal last year. These include requirements for data exclusivity of “at least five years” for small molecules and “at least eight years” for biological drugs, as well as patent-term extensions (Generics bulletin, 24 November 2017, page 1). All CPTPP members would have to agree to reinstate such measures for them to apply in future.

“Under CPTPP, there is no requirement for any party to change its data or market protection settings for new medicines, including small-molecule medicines, biological medicines and medicines that contain a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Generics Bulletin, or if you love it how it is, now is the time to have your voice heard.

Is Towa’s Guidance For 2024 ‘Somewhat Mediocre?’

 
• By Dean Rudge

Bringing in sales that translated to nearly $1.5bn last year, Japan’s Towa was feeling upbeat after a challenging few years, both for itself and the broader Japanese generics market. However, its financial guide for the next 12 months has left investors feeling cold.

Publisher’s Spotlight: Citeline News And Insights App

 
• By Generics Bulletin Team

Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.

More from Generics Bulletin

Fresenius Adds To Denosumab Competitors In Europe

 
• By Dave Wallace

At a busy meeting of the CHMP, the EMA issued positive opinions for Fresenius Kabi’s denosumab rivals to Prolia and Xgeva, another denosumab biosimilar from Sandoz, a Tecfidera hybrid from Neuraxpharm and a Descovy generic from Viatris. Meanwhile, Ascend has withdrawn a teriparatide filing.

Alvotech And Advanz Add Three More In €160m EU Partnership Expansion

 
• By Dean Rudge

Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By Dean Rudge

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.